Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan

Please use this identifier to cite or link to this item: http://ir.sinica.edu.tw/handle/201000000A/83304

Title:	Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
Authors:	Hsieh, SM Liu, MC Chen, YH Lee, WS Hwang, SJ Cheng, SH Ko, WC Hwang, KP Wang, NC Lee, YL Lin, YL Shih, SR Huang, CG Liao, CC Liang, JJ Chang, CS Chen, C Lien, CE Tai, IC Lin, TY
Issue Date:	2021-12
Relation:	The Lancet. Respiratory medicine 9(12), 1396-1406
URI:	http://ir.sinica.edu.tw/handle/201000000A/83304
URL:	http://dx.doi.org/10.1016/S2213-2600(21)00402-1
Appears in Collections:	生物醫學科學研究所

Show full item record

145

Last Week
8

Last month

checked on Dec 13, 2025

Check